Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EPS (Weighted Average and Diluted) (2018 - 2025)

Marimed has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at -$0.01 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 50.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Dec 2025, down 50.0% year-over-year, with the annual reading at -$0.04 for FY2025, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.01 for Q4 2025 at Marimed, roughly flat from -$0.01 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.02 in Q2 2021 and troughed at -$0.02 in Q4 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.0 (2023), against an average of -$0.0.
  • Year-over-year, EPS (Weighted Average and Diluted) surged 521.76% in 2021 and then crashed 282.27% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.02 in 2021, then skyrocketed by 200.0% to $0.02 in 2022, then tumbled by 200.0% to -$0.02 in 2023, then increased by 0.0% to -$0.02 in 2024, then soared by 50.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EPS (Weighted Average and Diluted) are -$0.01 (Q4 2025), -$0.01 (Q3 2025), and -$0.0 (Q2 2025).